Top 13 of 2013 — key developments in patent law and a look at what’s coming up in 2014
This year is already shaping up to be a big year in the world of patents, with a number of Full Federal Court decisions due to be handed down on important issues including the patentability of computer software, gene patents and perhaps the long-running Apple v Samsung litigation.
In anticipation of what’s to come, Minter Ellison has taken the opportunity to reflect on and examine what was also a bumper year for patents in Australia. The year saw: the introduction of the Raising the Bar amendments, which fundamentally changed Australian patent law; the courts grappling with the issue of patentable subject matter in the gene and software patent space; ahd the first High Court decision concerning patent law in a decade, which addressed methods of medical treatment and contributory infringement…
Click on the link below to read the rest of the Minter Ellison briefing.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Minter Ellison
News from The Lawyer
Briefings from Minter Ellison
Asia Region Funds Passport: draft rules a step towards a regional market for managed investment funds
The Asia Region Funds Passport will create a regional market for managed investment funds and give Australian fund managers an opportunity to increase their presence in Asia.
The Federal Court of Australia has dismissed the ACCC’s anti-competitive conduct case against Pfizer, finding that Pfizer did not breach the prohibition on misuse of market power.